Other drugs that rose in price this year include the pain medication Oxycontin and the antidepressant Wellbutrin
Pharmaceutical companies have raised prices for hundreds of medications in 2024, new research shows.
46Brooklyn Research, a nonprofit drug-pricing analytics group, recently released data that showed some drugmakers had raised the prices of their medications already this year, including popular drugs Ozempic and Mounjara, with some increases at 9% or higher.
Companies including Novo Nordisk — which produces Ozempic, a drug designed to help diabetics regulate their blood sugar that has also been found to be effective for weight loss — and Eli Lilly, which sells the similar drug Mounjaro, were on the list.
Per the data, the price of Ozempic rose 3.5% to $984.29 for a month's supply, while Mounjaro increased by 4.5% to about $960 for a month's worth of the medication.
Never miss a story — sign up for PEOPLE's free daily newsletter to stay up-to-date on the best of what PEOPLE has to offer, from celebrity news to compelling human interest stories.
Other drugs that had seen price increases include the autoimmune disease medication Enbrel, the pain medication Oxycontin, the blood thinner Plavix and the antidepressant Wellbutrin.
Enbrel, the data said, rose in cost by 5%, while Oxycontin increased by 9%, Plavix by 4.7% and Wellbutrin by 9.9%, the data adds.
46Brooklyn's data does not fully reflect what a consumer pays for a drug, however, as its analysis is based on the price that drugmakers charge to those who distribute the drugs to pharmacies, the company said.
Consumers can sometimes pay less due to factors such as insurance coverage or other discounts like rebates.
46Brooklyn also highlighted around two dozen medications that dropped in price at the start of the new year.
According to the nonprofit's data, the erectile dysfunction drug Cialis (19%) and the antidepressant Prozac (18%) declined, as did the chronic obstructive pulmonary disease medication Advair, which declined in price from 22% to 60%, depending on the formulation.
For more People news, make sure to sign up for our newsletter!
Read the original article on People.